EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudie

Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study

Anthony Buisson, Maria Nachury, Maud Reymond, Clara Yzet, Pauline Wils, Laure Payen, Marie Laugie, Luc Manlay, Nicolas Mathieu, Bruno Pereira, Mathurin Fumery

Clinical Gastroenterology and Hepatology · 2023-08 · 21 (9) · 2338-2346.e3

DOI: 10.1016/j.cgh.2022.08.011 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023-08. Verfasst von Anthony Buisson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hépato-Gastro Entérologie, 3iHP, INSERM, Centre Hospitalier Universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferra…. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Biosimilar Pharmaceuticals, Inflammatory Bowel Diseases. Die Arbeit wurde bisher 98-mal zitiert (Crossref) und nennt 15 Literaturangaben. Gefördert von: Celltrion Healthcare, Centre Hospitalier Universitaire de Clermont-Ferrand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND AIMS: We assessed the effectiveness of switching from intravenous to subcutaneous infliximab in patients with inflammatory bowel diseases (IBDs) treated with or without intensified intravenous regimen. METHODS: In this multicenter observational study, IBD patients in clinical remission (partial Mayo score ≤2 or Harvey-Bradshaw index ≤4) were switched to a unique dose of subcutaneous infliximab (120 mg every other week). Pharmacological and biological data were collected at baseline, visit 1 (4-8 weeks postswitch), visit 2 (8-16 weeks postswitch), and visit 3 (16-24 weeks postswitch). Relapse was defined as clinical relapse or fecal calprotectin increase ≥150 μg/g compared with baseline. RESULTS: Among 184 eligible patients, 72.3% (n = 133 of 184) agreed to switch to subcutaneous infliximab. At visit 3, a relapse occurred in 10.2% (n = 6 of 59), 7.3% (n = 3 of 38), 16.7% (n = 3 of 18), and 66.7% (n = 10 of 15) (P 250 μg/g at baseline (odds ratio, 5.4; 95% confidence interval, 1.1-27.6; P = .042) had a higher risk of relapse as well as reduced (41.7%) or stable (36.8%) infliximab serum levels between baseline and visit 1 compared with increased serum levels (12.7%) (P = .020 and P = .019, respectively). Patients' acceptability (10-point scale) was improved by the switch (6.9 ± 1.6 vs 8.6 ± 1.4; P < .0001). No severe adverse event was reported. CONCLUSIONS: Switching from intravenous to subcutaneous infliximab 120 mg every other week is safe and well accepted, leading to a low risk of relapse in IBD patients except for those receiving 10 mg/kg every 4 weeks requiring 240 mg every other week.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseBiosimilar PharmaceuticalsInflammatory Bowel DiseasesHumansInfliximabGastrointestinal AgentsLeukocyte L1 Antigen ComplexRecurrenceTreatment Outcome

Stichwörter der Autor:innen

Crohn’s DiseaseInfliximabSubcutaneousSwitchTrough LevelUlcerative Colitis

Substanzen

InfliximabGastrointestinal AgentsBiosimilar PharmaceuticalsLeukocyte L1 Antigen Complex

Autor:innen und Institutionen

  • Service d'Hépato-Gastro Entérologie, 3iHP, INSERM, Centre Hospitalier Universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France; M2iSH, USC-INRA 2018, INSERM U1071, 3iHP, Université Clerm…
  • INSERM U1286 - INFINITE - Institute for Translational Research in Inflammation, Centre Hospitalier Universitaire de Lille, Université de Lille, Lille, France.
  • Service d'Hépato-Gastro Entérologie, 3iHP, INSERM, Centre Hospitalier Universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.
  • Unité Peritox, Centre Hospitalier Universitaire de Amiens, Université de Picardie Jules Verne, Amiens, France.
  • Department of Hepato-Gastroenterology and Digestive Oncology, Grenoble Alpes University Hospital, Grenoble, France.
  • Unité de Biostatistiques, Direction de la Recherche Clinique et de l'Innovation, Centre Hospitalier Universitaire de Clermont-Ferrand, Université Clermont Auvergne, Clermont-Ferrand, France.

Förderung

  • Celltrion Healthcare
  • Centre Hospitalier Universitaire de Clermont-Ferrand

Zitieren

APA

Buisson, A., Nachury, M., Reymond, M., Yzet, C., Wils, P., Payen, L., Laugie, M., Manlay, L., Mathieu, N., Pereira, B., & Fumery, M. (2023). Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clinical Gastroenterology and Hepatology, 21(9), 2338-2346.e3. https://doi.org/10.1016/j.cgh.2022.08.011

Vancouver

Buisson A, Nachury M, Reymond M, Yzet C, Wils P, Payen L, et al. Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study. Clinical Gastroenterology and Hepatology. 2023;21(9):2338-2346.e3. doi:10.1016/j.cgh.2022.08.011

BibTeX
@article{Buisson2023,
  author = {Buisson, Anthony and Nachury, Maria and Reymond, Maud and Yzet, Clara and Wils, Pauline and Payen, Laure and Laugie, Marie and Manlay, Luc and Mathieu, Nicolas and Pereira, Bruno and Fumery, Mathurin},
  title = {Effectiveness of Switching From Intravenous to Subcutaneous Infliximab in Patients With Inflammatory Bowel Diseases: the REMSWITCH Study},
  journal = {Clinical Gastroenterology and Hepatology},
  year = {2023},
  volume = {21},
  number = {9},
  pages = {2338--2346.e3},
  doi = {10.1016/j.cgh.2022.08.011}
}
Kostenlos starten →